PMID- 27601952 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20160907 LR - 20200929 IS - 1507-1367 (Print) IS - 2083-4640 (Electronic) IS - 1507-1367 (Linking) VI - 21 IP - 3 DP - 2016 May-Jun TI - Image-guided hypofractionated proton beam therapy for low-risk prostate cancer: Analysis of quality of life and toxicity, PCG GU 002. PG - 207-12 LID - 10.1016/j.rpor.2016.01.002 [doi] AB - AIM: This interim analysis evaluated changes in quality of life (QOL), American Urological Association Symptom Index (AUA), or adverse events (AEs) among prostate cancer patients treated with hypofractionation. BACKGROUND: Results for hypofractionated prostate cancer with photon therapy are encouraging. No prior trial addresses the role of proton therapy in this clinical setting. MATERIALS AND METHODS: Forty-nine patients with low-risk prostate cancer received 38-Gy relative biologic effectiveness in 5 treatments. They received proton therapy at 2 fields a day, magnetic resonance imaging registration, rectal balloon, and fiducial markers for guidance pre-beam. We evaluated AEs, Expanded Prostate Index Composite (EPIC) domains, and AUA at pretreatment and at 3, 6, 12, 18, and 24 months. An AUA change >5 points and QOL change of half a standard deviation (SD) defined clinical significance. RESULTS: Median follow-up was 18 months; 17 patients reached follow-up of >/=24 months. For urinary function, statistically and clinically significant change was not seen (maximum change, 3). EPIC urinary QOL scores did not show statistically and clinically significant change at any end point (maximum, 0.45 SD). EPIC bowel QOL scores showed small but statistically and clinically significant change at 6, 12, 18, and 24 months (SD range, 0.52-0.62). EPIC sexual scores showed small but statistically and clinically significant change at 24 months (SD, 0.52). No AE grade >/=3 was seen. CONCLUSIONS: Patients treated with hypofractionated proton therapy tolerated treatment well, with excellent QOL scores, persistently low AUA, and no AE grade >/=3. FAU - Vargas, Carlos Enrique AU - Vargas CE AD - Department of Radiation Oncology, Mayo Clinic Hospital, Phoenix, AZ, USA. FAU - Hartsell, William Fred AU - Hartsell WF AD - CDH Proton Center, Warrenville, IL, USA. FAU - Dunn, Megan AU - Dunn M AD - Proton Collaborative Group, Warrenville, IL, USA. FAU - Keole, Sameer Ramchandra AU - Keole SR AD - Department of Radiation Oncology, Mayo Clinic Hospital, Phoenix, AZ, USA. FAU - Doh, Lucius AU - Doh L AD - Radiation Medicine Associates, PC, Radiation Oncology, Oklahoma City, OK, USA. FAU - Chang, John AU - Chang J AD - CDH Proton Center, Warrenville, IL, USA. FAU - Larson, Gary Lynn AU - Larson GL AD - Radiation Medicine Associates, PC, Radiation Oncology, Oklahoma City, OK, USA. LA - eng PT - Journal Article DEP - 20160304 PL - Poland TA - Rep Pract Oncol Radiother JT - Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology JID - 100885761 PMC - PMC5002029 OTO - NOTNLM OT - AE, adverse event OT - AUA, American Urological Association Symptom Index OT - Adverse events OT - American Urological Association Symptom Index OT - EPIC, Expanded Prostate Index Composite OT - Expanded Prostate Index Composite OT - OTV, optimization target volume OT - Quality of life OT - RBE, relative biologic effectiveness OT - RT, radiation therapy OT - SD, standard deviation OT - Stereotactic body radiation therapy EDAT- 2016/09/08 06:00 MHDA- 2016/09/08 06:01 PMCR- 2017/05/01 CRDT- 2016/09/08 06:00 PHST- 2015/08/24 00:00 [received] PHST- 2015/12/03 00:00 [revised] PHST- 2016/01/06 00:00 [accepted] PHST- 2016/09/08 06:00 [entrez] PHST- 2016/09/08 06:00 [pubmed] PHST- 2016/09/08 06:01 [medline] PHST- 2017/05/01 00:00 [pmc-release] AID - S1507-1367(16)00017-1 [pii] AID - 10.1016/j.rpor.2016.01.002 [doi] PST - ppublish SO - Rep Pract Oncol Radiother. 2016 May-Jun;21(3):207-12. doi: 10.1016/j.rpor.2016.01.002. Epub 2016 Mar 4.